Peptide science, clearly referenced.
Independent, literature-backed explainers on research compounds — every claim cited to PubMed, every framing strictly research-use-only.
Cibinetide was engineered to keep erythropoietin's tissue-protective signalling while abandoning its blood-building job. The molecular logic is elegant; the human evidence, gathered mostly in small neuropathy trials, is real but early.
A small molecule made untrained mice run dramatically further. Two decades and several large human trials later, acadesine's record is a study in how rodent spectacle and clinical reality diverge.
Humans carry a single cathelicidin. It kills microbes, calls in immune cells and helps wounds close — and, in the wrong context, teaches the immune system to attack its owner. A look at the most genuinely double-edged peptide in innate immunity.
GRF(1-29) is the rare growth-hormone peptide with a genuine regulatory past — approved, marketed as Geref, then withdrawn for commercial reasons. But its documented history is diagnosis and childhood deficiency, not the longevity claims now attached to it.
Elamipretide is the most clinically advanced cardiolipin-targeting tetrapeptide ever tested — now an approved Barth-syndrome drug, yet with a trial record that is the field's sharpest cautionary tale.
An FDA-approved cyclic peptide that acts in the brain rather than the blood vessels: a narrow indication, a modest effect, and a melanocortin tax of nausea and pigment.
The decapeptide that orders GnRH neurons when to fire is among the best-mapped pieces of human reproductive physiology — and, candidly, still a research tool rather than a finished medicine.
A 28-residue thymic peptide is licensed for hepatitis across dozens of countries and drew attention during COVID-19, yet remains unapproved by the FDA. The evidence is real, large, and frustratingly uneven.
A porcine brain-derived peptide mixture prescribed across Eastern Europe and Asia for stroke and dementia — yet independent reviews are tepid, and you cannot fully say what is in the vial.
A stabilised GHRH(1-44) analogue is the one growth-hormone secretagogue in this catalogue with a regulatory approval behind it. That approval is narrow, conditional, and routinely misread.